The cleavage of CD16 by ADAM17 leads to a decrease of CD16 binding avidity to antibody-coated target cells and in turn can suppress NK cells antitumor activity through ADCC, allowing cancer cells to create an immunosuppressive TME (34). Here, FCGR3A is linked to cancer.